Phase I, Phase I

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Volunteers
Health Professionals

What is the purpose of this trial?

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Michael Cecchini

michael.cecchini@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Michael Cecchini, MD
Associate Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers; Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine; Co-Director, GI Clinical Research Team; Phase 1 Investigator, Yale Cancer Center

Sub-Investigators

Last Updated
10/02/2024
Study HIC
#2000026742